Loading organizations...
§ Private Profile · New York City, NY, USA
Healthcare tech company. Cloud platform generates rapid RWE for clinicians, researchers, life science companies.
Based in Palo Alto, California, Atropos Health is a healthcare technology company that develops a cloud software platform to generate rapid real-world evidence reports from observational medical data. The enterprise software business allows clinicians, researchers, and life science professionals to query healthcare data using natural language and receive publication-grade retrospective observational studies within two days. To support its commercial growth, the company has raised more than $47 million in total disclosed funding, which includes a $33 million Series B financing round completed in May 2024. Atropos Health is backed by prominent venture capital investors including Valtruis, Breyer Capital, and Sanofi Ventures, and maintains a strategic cloud distribution partnership with AWS. Originally developed as a technology spinout from Stanford University, the enterprise was founded in 2020 by Brigham Hyde, Nigam Shah, and Saurabh Gombar.
Atropos Health has raised $47.0M across 2 funding rounds.
Atropos Health has raised $47.0M in total across 2 funding rounds.
Atropos Health has raised $47.0M in total across 2 funding rounds.
Atropos Health's investors include Mike Spadafore, BlueCross BlueShield Venture Partners, CVS Health, Oak HC/FT, Sandbox Industries, Breyer Capital, Cencora Ventures, Emerson Collective, Michelle Snyder, Merck, Presidio Ventures, Jim Breyer.
Atropos Health has raised $47.0M across 2 funding rounds. Most recently, it raised $33.0M Series B in May 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2024 | $33M Series B | Mike Spadafore | Bluecross Blueshield Venture Partners, CVS Health, OAK HC/FT, Sandbox Industries, Breyer Capital, Cencora Ventures, Emerson Collective, Michelle Snyder, Merck, Presidio Ventures | Announced |
| Aug 4, 2022 | $14M Series A | JIM Breyer | Boston Millennia Partners, Matt Bettonville | Announced |
Atropos Health is a healthcare technology company that develops the Atropos Evidence Platform (including GENEVA OS™), a cloud-based system enabling rapid generation of high-quality, personalized real-world evidence (RWE) from electronic medical records (EMR) and real-world data (RWD).[1][2][3] It serves healthcare organizations, life sciences companies, clinicians, and researchers by producing "Prognostograms"—individualized reports answering "What happened to patients like mine?"—to inform treatment decisions, close evidence gaps, optimize clinical trials, and drive value-based care.[1][2][3][4] The platform solves the problem of siloed, resource-intensive healthcare data analysis, which traditionally takes months, by delivering publication-grade observational studies in minutes at scale, with 100% peer-reviewed publication success, over 10K clinical questions addressed, and $100M in client savings.[1][3]
Growth momentum is strong: Founded in 2019, it raised $33M in Series B funding in 2023 to scale automation and expand into life sciences, partnering with entities like Janssen R&D, Arcadia, and Google Cloud's Gemini AI for faster insights.[3][5][7] This positions Atropos as a leader in evidence-based medicine for complex, comorbid patients often excluded from traditional research.[2][6]
Atropos Health originated as the "Green Button" project at Stanford University, evolving into a company founded in 2019 by Brigham Hyde, Ph.D. (CEO), Nigam Shah, MBBS, Ph.D., and Saurabh Gombar, M.D., Ph.D. (CMO)—experts in AI, RWE, and clinical informatics.[3][2] The idea emerged from a decades-long vision since the 1970s to use real-world patient data for on-demand evidence, addressing how over 80% of care decisions lack reliable clinical backing, especially for comorbid patients.[2][1] Early traction came from the patented Evidence Platform, built on over a decade of technology, research, and clinical progress, enabling physician-led services to fulfill data-driven medicine's promise.[1][2]
Pivotal moments include launching the Green Button Clinical Informatics Consult Service, achieving dozens of peer-reviewed publications (e.g., Cell, NEJM Catalyst), and securing partnerships that demonstrated real-world impact, like expediting analytics and policy changes.[1][3][4]
Atropos rides the RWE and AI-in-healthcare wave, fueled by abundant but siloed EMR data and demands for value-based care amid rising costs and drug pricing pressures.[1][3][6] Timing is ideal post-2020s data explosion and regulatory pushes for RWE in approvals, enabling faster, smaller precision trials and inclusive research for diverse populations.[2][4][6] Market forces like health equity mandates, AI advancements (e.g., Gemini integration), and life sciences' need for bench-to-bedside evidence favor Atropos, transforming workflows for providers, pharma, and researchers.[5][7]
It influences the ecosystem by democratizing evidence access, promoting diversity in trials, and automating high-value care—potentially reducing disparities and accelerating therapies for complex patients.[3][4][6]
Atropos Health is poised to dominate RWE automation, expanding GENEVA OS™ across healthcare and life sciences with AI enhancements and partnerships like Janssen.[3][5][7] Trends like multimodal AI, federated data networks, and regulatory RWE adoption will amplify its speed and inclusivity, potentially capturing more value-based care market share. Its influence may evolve from consult service to full evidence OS, redefining personalized medicine and trial design. This mission to back every decision with trusted RWE cements Atropos as the currency of value in a data-rich healthcare future.[1][3]